Regeneron (REGN) Tops Q1 EPS by 53c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- U.S. economy adds 172,000 jobs in May, topping expectations
- Citi warns global stock markets are the frothiest since 2008
- JPMorgan upgrades Tesla, sets new price target on robotaxi and Optimus potential
- Fed risks fueling a stock bubble by overlooking AI-driven inflation: BCA
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- SpaceX signs $920 million monthly cloud deal with Google
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
Regeneron Reports First Quarter 2023 Financial and Operating Results
May 4, 2023 6:30 AM EDTFirst quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022First quarter 2023 EYLEA® U.S. net sales were $1.43 billionFirst quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPS(a) of $10.09; includes unfavorable $0.42 impact from acquired IPR&D chargeEuropean Commission approved Dupixent for atopic dermatitis in children aged 6 months to 5 years and Libtayo® in combination with chemotherapy for advanced PD-L1 positive non-small... More
